Skip to main content
GileadPatent grant

Gilead Sciences was granted a patent for PRMT5-inhibiting cancer medicines.

Source: Autobound Signal API · 74 signals tracked for Gilead · updated

Get Gilead's live signals in Claude or ChatGPT, or by API

AskWhat changed at Gilead this week? Use Autobound signals for gilead.com.

What happened

In November 2026 Gilead Sciences patented drug compounds intended for treating cancers and other conditions involving chromosome 9p21 deletion or MTAP loss.

Source

patents.google.comNov 17, 2026

US patent US12799113

PRMT5 inhibitors and uses thereof

Abstract

The present disclosure relates generally to compounds that inhibit PRMT5. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through inhibiting PRMT5. The disclosure further relates to the use of the compounds for the treatment of a disease or condition associated with chromosome 9p21 deletion or MTAP null. The disclosure further relates to the use of the compounds for the treatment of cancers.

patents.google.com/patent/US12799113Read the full source

Extracted by Autobound

From the Signal API record
Signal
Patent grant

What this signalsA new patent often shows where a company is putting its R&D budget.

Grant date
Nov 17, 2026
Inventors
4
Patent number
US12799113
Assignee
Gilead Sciences, Inc.

The full record

From the Signal API record

People

  • Megan K. ArmstrongInventor
  • Elbert ChinInventor
  • Chienhung ChouInventor
  • Laurent P. DebienInventor
  • Joshua D. FarrInventor
  • Pancham Lal GuptaInventor

Details

Primary CPC class
C07D 471/04
USPTO assignee
Gilead Sciences, Inc.
What the invention does
A group of chemical compounds designed to block PRMT5, a protein target linked to certain cancers, particularly those with MTAP loss.

Topics and mentions

Tags

  • Intellectual Property
  • Research & Development
  • Pharmaceuticals
  • Medical Research

Technologies named

  • PRMT5 inhibitors
  • medicinal chemistry
  • oncology therapeutics

Extraction

Detected
Nov 18, 2026
signal_type
patents-company
signal_subtype
patentGrant

Use this data

Get every patent signal for Gilead and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Gilead this week?”

  2. Send it to your own tools

    The Signal API returns patent signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full patents-company record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/0912db90-8529-5f49-9098-5d0c716376e1 returns this record as JSON. POST /v1/companies/enrich returns every signal for gilead.com.

{
  "signal_id": "0912db90-8529-5f49-9098-5d0c716376e1",
  "signal_type": "patents-company",
  "signal_subtype": "patentGrant",
  "detected_at": "2026-11-18T15:07:07+00:00",
  "company": {
    "name": "Gilead",
    "domain": "gilead.com"
  },
  "data": {
    "cpc": [
      {
        "code": "C07D 471/04"
      },
      {
        "code": "A61K 31/473"
      },
      {
        "code": "A61K 31/4741"
      },
      {
        "code": "A61K 31/4743"
      },
      {
        "code": "A61K 31/4745"
      }
    ],
    "tags": [
      "Intellectual Property",
      "Research & Development",
      "Pharmaceuticals",
      "Medical Research"
    ],
    "detail": "In November 2026 Gilead Sciences patented drug compounds intended for treating cancers and other conditions involving chromosome 9p21 deletion or MTAP loss.",
    "summary": "Gilead Sciences was granted a patent for PRMT5-inhibiting cancer medicines.",
    "event_at": "2026-11-17",
    "inventors": [
      {
        "name": "Megan K. Armstrong",
        "status": "resolved",
        "is_primary": true,
        "linkedin_url": "https://www.linkedin.com/in/megan-armstrong-1ba40a189"
      },
      {
        "name": "Elbert Chin",
        "status": "resolved",
        "is_primary": false,
        "linkedin_url": "https://www.linkedin.com/in/elbert-chin-16497222"
      },
      {
        "name": "Chienhung Chou",
        "status": "unresolved",
        "is_primary": false
      },
      {
        "name": "Laurent P. Debien",
        "status": "resolved",
        "is_primary": false,
        "linkedin_url": "https://www.linkedin.com/in/laurent-debien-362b1299"
      },
      {
        "name": "Joshua D. Farr",
        "status": "resolved",
        "is_primary": false,
        "linkedin_url": "https://www.linkedin.com/in/joshua-farr-2b455515a"
      },
      {
        "name": "Pancham Lal Gupta",
        "status": "resolved",
        "is_primary": false,
        "linkedin_url": "https://www.linkedin.com/in/panchamlalgupta"
      },
      {
        "name": "Chao-I Hung",
        "status": "unresolved",
        "is_primary": false
      },
      {
        "name": "Michael L. Mitchell",
        "status": "unresolved",
        "is_primary": false
      }
    ],
    "event_kind": "grant_date",
    "grant_date": "2026-11-17",
    "source_url": "https://patents.google.com/patent/US12799113",
    "cpc_primary": {
      "code": "C07D 471/04"
    },
    "patent_title": "PRMT5 inhibitors and uses thereof",
    "patent_number": "US12799113",
    "uspto_assignee": "Gilead Sciences, Inc.",
    "patent_abstract": "The present disclosure relates generally to compounds that inhibit PRMT5. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through inhibiting PRMT5. The disclosure further relates to the use of the compounds for the treatment of a disease or condition associated with chromosome 9p21 deletion or MTAP null. The disclosure further relates to the use of the compounds for the treatment of cancers.",
    "precision_class": "structural",
    "invention_explanation": "A group of chemical compounds designed to block PRMT5, a protein target linked to certain cancers, particularly those with MTAP loss.",
    "technologies_mentioned": [
      "PRMT5 inhibitors",
      "medicinal chemistry",
      "oncology therapeutics"
    ]
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.